Mainz Biomed B.V. (NASDAQ: MYNZ) – Fundamental Analysis

Mainz Biomed BV (NASDAQ: MYNZ) is engaged in developing molecular genetic diagnostic solutions for life-threatening conditions. It’s main product Coloalert is a kit that includes a stool collector and shipping instructions to return the kit through regular mail to their local lab for testing and results.

4 Key Reasons To Get This Potentially Undervalued Idea On Your Radar ASAP

​

• The Company’s Flagship Product (ColoAlert) Could Become An Inexpensive Alternative In A $3.7 Billion Market
• The Company Recently Acquired Exclusive Rights To Novel mRNA Biomarkers
• If And When The Company Receives FDA Premarket Approval For Its ColoAlert Flagship Product, It Could Become A Game-Changing Milestone
• Another Key Pipeline Product Could Detect What May Become The World’s Second Most Deadly Cancer

That's how Mainz BioMed could take full advantage of a $3.7 BILLION market opportunity with its blockbuster early detection test for Colorectal Cancer. This is the perfect add to watch-list stock and do your due diligence.

This business has huge potential, so check out this article for a further analysis on the company.

https://markettradersreport.com/molecular-genetics/?utm_source=dmreddit&utm_medium=influencer&utm_campaign=mynzz_us

…

Disclaimer: “This User has been paid $200USD by a third party to provide coverage on 05/30-03/2022 for Mainz Biomed B.V. (MYNZ).”